Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer - Poll - MDSpire

Emerging Immunotherapeutic Agents in Initial Clinical Trials for Head and Neck Malignancies

  • By

  • Harold Nathan Tan

  • Bettzy Stephen

  • Oriol Mirallas

  • Mohamed H. Derbala

  • Israa Salih

  • Lilibeth Castillo

  • Yali Yang

  • Hung Le

  • Lei Kang

  • Heather Lin

  • Joann Lim

  • Ecaterina E. Dumbrava

  • Timothy A. Yap

  • Jordi Rodón

  • Sarina A. Piha-Paul

  • Siqing Fu

  • Stéphane Champiat

  • Neal Akhave

  • Renata Ferrarotto

  • David S. Hong

  • Funda Meric-Bernstam

  • Faye Johnson

  • Aung Naing

  • July 16, 2026

Share

Original Source(s)

Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer

  • by Harold Nathan Tan, Bettzy Stephen, Oriol Mirallas, Mohamed H. Derbala, Israa Salih, Lilibeth Castillo, Yali Yang, Hung Le, Lei Kang, Heather Lin, Joann Lim, Ecaterina E. Dumbrava, Timothy A. Yap, Jordi Rodón, Sarina A. Piha-Paul, Siqing Fu, Stéphane Champiat, Neal Akhave, Renata Ferrarotto, David S. Hong, Funda Meric-Bernstam, Faye Johnson, Aung Naing

  • July 16, 2026

Related Content

Development and internal validation of a prognostic nomogram incorporating F-NLR and HAGR scores in patients with oral squamous cell carcinoma: a single-center retrospective cohort study

ORC6 marks a replication-active malignant epithelial state and is associated with immune-low features in oral squamous cell carcinoma

Clinical features and treatment challenges of HER2-positive primary breast squamous cell carcinoma: a case report and literature review